Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With EGFR T790M Mutation”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT03452592
What this trial is testing

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Who this might be right for
Advanced NSCLC Patients With T790M
Allist Pharmaceuticals, Inc. 220
Testing effectiveness (Phase 2)UnknownNCT03758287
What this trial is testing

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Who this might be right for
Non-small Cell Lung Cancer
Sunshine Lake Pharma Co., Ltd. 158
Testing effectiveness (Phase 2)UnknownNCT03257124
What this trial is testing

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Who this might be right for
Non-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase Inhibitors
Samsung Medical Center 80
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Large-scale testing (Phase 3)Study completedNCT02474355
What this trial is testing

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 3,017
Testing effectiveness (Phase 2)Study completedNCT02759835
What this trial is testing

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Who this might be right for
Lung AdenocarcinomaLung Neoplasms
National Cancer Institute (NCI) 37
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT03228277
What this trial is testing

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Who this might be right for
Non Small Cell Lung Cancer
Konkuk University Medical Center 25
Testing effectiveness (Phase 2)UnknownNCT03706287
What this trial is testing

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Who this might be right for
Lung Cancer Metastatic
Sichuan Cancer Hospital and Research Institute 62
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Study completedNCT01802632
What this trial is testing

AZD9291 First Time In Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 603
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Early research (Phase 1)Study completedNCT01647711
What this trial is testing

Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 35
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Study completedNCT03812809
What this trial is testing

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Who this might be right for
NSCLC
Beta Pharma Shanghai 226
Early research (Phase 1)Study completedNCT02914990
What this trial is testing

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 36
Load More Results